Lonza Seen With Upside to Guidance Thanks to New Market Opportunities -- Market Talk
Lonza Seen With Upside to Guidance Thanks to New Market Opportunities -- Market Talk
1019 GMT - Lonza's growth is underpinned by an increasing outsourcing trend among big pharma companies and the biotech industry, where a strong funding background is giving Lonza new customers, Credit Suisse says. In the mid term, new market opportunities such as in Alzheimer's could provide upside to guidance for the Swiss biotech and chemical company, according to Credit Suisse. Mid-term margins are seen around 33% to 35% despite near-term operating expenses for capacity expansion, the bank says. Lonza trades 2.7% higher at CHF717.60. ( cecilia.butini@wsj.com)
1019GMT-瑞士信貸(Credit Suisse)表示，龍沙的增長得到了大型製藥公司和生物技術行業日益增長的外包趨勢的支撐，在這些行業，強大的資金背景正在為龍沙帶來新的客户。瑞士信貸(Credit Suisse)表示，中期內，阿爾茨海默氏症等新的市場機遇可能會為這家瑞士生物技術和化工公司提供上行指引。該行表示，儘管近期產能擴張的運營費用較高，但中期利潤率預計在33%至35%左右。龍沙股價上漲2.7%，至717.60瑞士法郎。(cecilia.butini@wsj.com)
譯文內容由第三人軟體翻譯。